| T16021 |
MBQ-167
|
2097938-73-1
|
98.07%
|
|
|
MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).
|
| T13058 |
T025
|
2407433-00-3
|
98.08%
|
|
|
T025 is a pan CLK inhibitor with Kds of 4.8, 0.096, 6.5, 0.61, and 0.074 nM for CLK1-4, respectively. T025 displays anti-proliferative activities with IC50s of 3...
|
| T77810 |
XPW1
|
2700286-66-2
|
98.08%
|
|
|
XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used...
|
| T74710 |
YX-2-107
|
2417408-46-7
|
98.09%
|
|
|
YX-2-107 is a selective and potent CDK6-degrading PROTAC with an IC50 value of 4.4 nM.YX-2-107 inhibits RB phosphorylation and FOXM1 expression in vitro, and inh...
|
| T9083 |
TC11
|
100823-03-8
|
98.1%
|
|
|
TC11 (1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-TC11) is a potent inhibitor of tumor cell proliferation and an inducer of apoptosis vi...
|
| T14919 |
CDKI-73
|
1421693-22-2
|
98.11%
|
|
|
CDKI-73 is a potent CDK9 inhibitor (Ki: 4 nM). It shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).The in...
|
| T10744L |
SEL120-34A HCl
|
1609452-30-3
|
98.13%
|
|
|
SEL120-34A HCl is a selective, orally available and ATP-competitive inhibitor of CDK8(CDK8/CycC and CDK19/CycC with IC50s of 4.4 nM and 10.4 nM , respectively), ...
|
| T10745 |
CDK9-IN-7
|
2369981-71-3
|
98.19%
|
|
|
CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/c...
|
| T34888 |
TL12-186
|
2250025-88-6
|
98.2%
|
|
|
TL12-186 is a Cereblon-dependent kinase degrader that degrades CDK, BTK, FLT3, Aurora and other kinases.TL12-186 inhibits CDK2/cyclin A and CDK9/cyclin T1 with I...
|
| T10659 |
Ca2+ channel agonist 1
|
1402821-24-2
|
98.21%
|
|
|
Ca2+ channel agonist 1 is an agonist of N-type Ca2+ channel and an inhibitor of Cdk2 (EC50s: 14.23 μM and 3.34 μM) and is used as a potential treatment for motor...
|
| T4051 |
LDC4297
|
1453834-21-3
|
98.25%
|
|
|
LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.
|
| T9138 |
Indirubin-3′-oxime
|
667463-82-3
|
98.26%
|
|
|
Indirubin-3′-oxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.
|
| T15204 |
EHT 1610
|
1425945-60-3
|
98.27%
|
|
|
EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively. EHT 1610 has an inhibitory effect on ...
|
| T16391 |
ON-013100
|
865783-95-5
|
98.27%
|
|
|
ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.
|
| T6199 |
Ribociclib
|
1211441-98-3
|
98.27%
|
|
|
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).
|
| T1830 |
BX795
|
702675-74-9
|
98.32%
|
|
|
BX795 is an effective and selective PDK1 inhibitor (IC50: 6 nM), and its selectivity is 140- and 1600-fold for PDK1 over PKA and PKC in cell-free assays, respect...
|
| T9636 |
Dalpiciclib
|
1637781-04-4
|
98.32%
|
|
|
Dalpiciclib (SHR-6390) is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4 nM and 9.9 nM, respective...
|
| T2679 |
BMS-265246
|
582315-72-8
|
98.33%
|
|
|
BMS-265246 is a potent and selective CDK1/2 inhibitor.
|
| T35332 |
THZ1 2HCl
|
2095433-94-4
|
98.33%
|
|
|
THZ1 2HCl (THZ1 Dihydrochloride) is a selective, covalent, and allosteric inhibitor of CDK7 with an IC50 of 3.2 nM. THZ1 2HCl has antiproliferative effects on a ...
|
| T6028 |
PF 477736
|
952021-60-2
|
98.34%
|
|
|
PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CS...
|
